(Il Sole 24 Ore Radiocor) – New York, 07 July – Whether Mylan will change his mind remains to be seen. So far, the group has strongly opposed the takeover as it unsuccessfully attempted to buy Perrigo, another generics maker, in an unwelcome move.
Teva's advances are complicated by the fact that Mylan has been based in the Netherlands since last year it acquired the foreign assets of US rival Abbott Laboratories in a "tax inversion" deal.
With the stake in Mylan raked up last month, Teva is for the first time able to present a formal takeover proposal based on Dutch law. But there are other legal hurdles to overcome. In the pre-market, Teva rose by half a percentage point, Mylan by 0.9% to 71.4 dollars.
A24-Spa
(RADIOCOR) 07-07-15 13:53:15 (0355) 5 NNNN
